June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Systemic adverse events after antiangiogenic therapy in clinical trials comparing Bevacizumab and Ranibizumab
Author Affiliations & Notes
  • Jose Lorenzo Carrero
    Ophthalmology, Povisa Hospital, Vigo, Spain
  • Alexandros Deligiannidis
    Ophthalmology, Povisa Hospital, Vigo, Spain
  • Footnotes
    Commercial Relationships Jose Lorenzo Carrero, None; Alexandros Deligiannidis, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 249. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jose Lorenzo Carrero, Alexandros Deligiannidis; Systemic adverse events after antiangiogenic therapy in clinical trials comparing Bevacizumab and Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2013;54(15):249. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To examine and compare the evidence of incidental severe systemic adverse events one year after antiangiogenic therapy with Ranibizumab and Bevacizumab.

Methods: We searched CENTRAL, MEDLINE, EMBASE. There were no date or language restrictions in the electronic searches for trials. We included all randomised controlled trials (RCTs) comparing bevacizumab and ranibizumab. we examine the ocurrence of systemic serious adverse events. We pooled data using a fixed-effect model.

Results: We included three RCTs in this review. Overall the quality of the evidence was high. There were 1795 treated patients; 882 with bevacizumab, and 913 with ranibicizumab. The pooled risk difference for systemic adverse events was 0.001 (p=0.265). An analysis by specific event showed that the risk difference for gastrointestinal disorders was 0.017 more frequent in patients undergoing bevacizumab treatment (p=0.003).

Conclusions: Though reviewed RCTs were not specifically designed to detect any difference in adverse outcomes, pooled data show that both treatments are comparably safe, except for differences found in the ocurrence of Gastrointestinal disorders which could be related to the baseline differences in medical conditions of participants.

Keywords: 561 injection • 503 drug toxicity/drug effects  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.